62 research outputs found
Subgroup estimation of the effects of fish oil on BMI changes.
<p>Subgroup estimation of the effects of fish oil on BMI changes.</p
Image_1_The value of G-CSF in women experienced at least one implantation failure: a systematic review and meta-analysis.tif
ObjectiveDespite the developments of in vitro fertilization (IVF) protocols, implantation failure remains a challenging problem, owing to the unbalance between the embryo, endometrium, and immune system interactions. Effective treatments are urgently required to improve successful implantation. Recently, many researchers have focused on granulocyte colony-stimulating factor (G-CSF) to regulate immune response and embryo-endometrium cross-talk. However, previous studies have reported inconsistent findings on the efficacy of G-CSF therapy on implantation failure. The objective of this review was to further explore the effects of G-CSF according to administration dosage and timing among women who experienced at least one implantation failure.MethodsWe systematically searched MEDLINE, Embase, the Cochrane Central Register of Controlled Trials, Scopus, and Web of Science for randomized controlled trials of G-CSF on implantation failure up to July 21, 2023. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated and the heterogeneity of the studies with the I2 index was analyzed.ResultsWe identified a total of 2031 studies and finally included 10 studies in the systematic review and meta-analysis. G-CSF administration improved the clinical pregnancy rate (CPR), implantation rate (IR), biochemical pregnancy rate (BPR), and live birth rate (LBR) in women with at least one implantation failure. Subgroup analyses showed that G-CSF treatment could exert good advantages in improving CPR [OR=2.49, 95%CI (1.56, 3.98), I2Ā =Ā 0%], IR [OR=2.82, 95%CI (1.29, 6.15)], BPR [OR=3.30, 95%CI (1.42, 7.67)] and LBR [OR=3.16, 95%CI (1.61, 6.22), I2Ā =Ā 0%] compared with the blank control group. However, compared with placebo controls, G-CSF showed beneficial effects on CPR [OR=1.71, 95%CI (1.04, 2.84), I2Ā =Ā 38%] and IR [OR=2.01, 95%CI (1.29, 3.15), I2Ā =Ā 24%], but not on LBR. In addition, >150Ī¼g of G-CSF treatment increased CPR [OR=2.22, 95%CI (1.47, 3.35), I2Ā =Ā 0%], IR [OR=2.67, 95%CI (1.47, 4.82), I2Ā =Ā 0%] and BPR [OR=2.02, 95%CI (1.17, 3.47), I2Ā =Ā 22%], while ā¤150Ī¼g of G-CSF treatment improved miscarriage rate (MR) [OR=0.14, 95%CI (0.05, 0.38), I2Ā =Ā 0%] and LBR [OR=2.65, 95%CI (1.56, 4.51), I2Ā =Ā 0%]. Moreover, G-CSF administration on the day of embryo transfer (ET) could increase CPR [OR=2.81, 95%CI (1.37, 5.75), I2Ā =Ā 0%], but not on the day of ovum pick-up (OPU) or human chorionic gonadotropin (HCG) injection.ConclusionG-CSF has a beneficial effect on pregnancy outcomes to some extent among women who experienced at least one implantation failure, and the administration dosage and timing influence the effect size.Systematic review registrationhttps://www.crd.york.ac.uk/prospero/, identifier CRD42023447046.</p
Forest plots from meta-analyses for the effects of fish oil on changes in body weight (A), BMI (B), waist circumference (C), and WHR (D).
<p>Forest plots from meta-analyses for the effects of fish oil on changes in body weight (A), BMI (B), waist circumference (C), and WHR (D).</p
Does Fish Oil Have an Anti-Obesity Effect in Overweight/Obese Adults? A Meta-Analysis of Randomized Controlled Trials
<div><p>Context</p><p>Accumulating evidence has suggested favorable effects of fish oil on weight loss in animal experiments; however, findings remain inconsistent in humans.</p><p>Objects</p><p>The meta-analysis was performed to investigate the influence of fish oil on some parameters of body composition in overweight/obese adults.</p><p>Design</p><p>Human randomized, placebo-controlled trials were identified by a systematic search of Embase, PubMed, the Cochrane Library, web of science and reference lists of related reviews and articles. The random-effects model was used to estimate the calculated results.</p><p>Results</p><p>In total, 21 studies with 30 study arms were included in this analysis. Calculated results of the meta-analysis demonstrated that fish oil had no effect on reducing body weight (overall SMD = -0.07, 95% CI -0.21 to 0.07, <i>P</i> = 0.31) and BMI (overall SMD = -0.09, 95% CI -0.22 to 0.03, <i>P</i> = 0.14) whether alone or combined with life modification intervention in overweight/obese subjects. However, waist circumference was significantly reduced (SMD = -0.23, 95% CI -0.40 to -0.06, <i>P</i> = 0.008) in those with fish oil supplementation combined with life modification intervention. Waist hip ratio (WHR) was significantly reduced (overall SMD = -0.52 95% CI -0.76 to -0.27, <i>P</i> < 0.0005) in fish oil supplemented individuals with or without combination life modification intervention.</p><p>Conclusion</p><p>Current evidence cannot support an exact anti-obesity role of n-3 polyunsaturated fatty acids (PUFAs) in overweight/obese subjects. However, these subjects may benefit from reducing abdominal fat with fish oil supplementation especially when combined with life modification intervention. Further large-scale and long-term clinical trials are needed to gain definite conclusions.</p></div
Overview and characteristics of included studies.
<p>NR, not reported; PCOS, polycystic ovary syndrome; T2DM, type 2 diabetes; Met S, metabolic syndrome; Wt, body weight; BMI, body mass index; WHR, waist hip ratio; WC, waist circumference.</p><p>General health, overall health status apart from overweight/obese.</p><p>The study by Thorsdottir et al had a fish oil capsules group (1.5 g/d EPA + DHA) and fatty fish diet group (3g/d EPA+DHA).</p><p>The study by Crochemore et al was given fish oil capsules with 0.54 or 0.9 g/d EPA +DHA.</p><p>The study by Sjoberg et al was given fish oil capsules with 0.64, 1.28, or 1.92g/d EPA +DHA.</p><p>The study by Moore et al compared 4.5g/week EPA+DHA plus rapeseed oil with 0.7g/week EPA+DHA plus rapeseed oil; 4.5g/week EPA+DHA plus sunflower oil with 0.7g/week EPA+DHA plus sunflower oil.</p><p>The studies by Mori, Hill, and Munro et al included comparisons with participants underwent fish oil alone or combined with weight loss program.</p><p>Overview and characteristics of included studies.</p
Subgroup estimation of the effects of fish oil on body weight changes.
<p>Subgroup estimation of the effects of fish oil on body weight changes.</p
PRISMA 2009 flow diagram illustrates the study selection procedure.
<p><i>From</i>: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). <i>P</i>referred <i>R</i>eporting <i>I</i>tems for <i>S</i>ystematic Reviews and <i>M</i>eta-<i>A</i>nalyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097. <b>For more information, visit</b><a href="http://www.prisma-statement.org" target="_blank">www.prisma-statement.org</a>.</p
Relative Contribution of Fasting and Postprandial Blood Glucose in Overall Glycemic Control: Post-Hoc Analysis of a Phase IV Randomized Trial
<p></p><p><b>Article full text</b></p>
<p><br></p>
<p>The full text of this article can
be found here<b>.</b> <a href="https://link.springer.com/article/10.1007/s13300-018-0403-7">https://link.springer.com/article/10.1007/s13300-018-0403-7</a></p><p></p><p></p><p>
</p><p><br></p>
<p><b>Provide enhanced content for this
article</b></p>
<p><br></p>
<p>If you are an author of this
publication and would like to provide additional enhanced content for your
article then please contact <a href="http://www.medengine.com/Redeem/Ć¢ĀĀmailto:[email protected]Ć¢ĀĀ"><b>[email protected]</b></a>.</p>
<p><br></p>
<p>The journal offers a range of
additional features designed to increase visibility and readership. All
features will be thoroughly peer reviewed to ensure the content is of the
highest scientific standard and all features are marked as āpeer reviewedā to
ensure readers are aware that the content has been reviewed to the same level
as the articles they are being presented alongside. Moreover, all sponsorship
and disclosure information is included to provide complete transparency and
adherence to good publication practices. This ensures that however the content
is reached the reader has a full understanding of its origin. No fees are
charged for hosting additional open access content.</p>
<p><br></p>
<p>Other enhanced features include,
but are not limited to:</p>
<p><br></p>
<p>ā¢ Slide decks</p>
<p>ā¢ Videos and animations</p>
<p>ā¢ Audio abstracts</p>
<p>ā¢ Audio slides</p><br><p></p
Cationic Ring-Opening Photopolymerization of Long-Chain Epoxides in the Rotator Phase: Confirmation, Mechanism, and Combination
Rotator-phase photopolymerization has been developed
in the field
of free-radical addition polymerization since the photopolymerization
in the rotator phase was first proposed, and other mechanisms urgently
need to be extended. Herein, four long-chain glycidyl ethers were
synthesized, and their polymorphic behavior was studied by differential
scanning calorimetry and X-ray diffraction. Among all, the octadecyl
glycidyl ether (OGE) and the hexadecyl glycidyl ether (HGE) are proven
existing rotator phases. The cationic ring-opening photopolymerization
of the OGE in the rotator phase was achieved, and the highest conversion
reached 68.6% at 30 Ā°C, which is even higher than that of liquid-state
photopolymerization at adjacent higher temperatures (27.2% at 40 Ā°C).
The mechanism was discussed and explained with the aid of a molecular
dynamic simulation. In order to further develop the cationic ring-opening
photopolymerization in rotator phases at relatively low temperatures,
three types of long-chain compounds were chosen to separately blend
with the OGE to construct binary systems. The conversion of the OGE
at 20 Ā°C (17% in the pure OGE system) could be obviously improved
in all binary systems, and the maximum conversion could reach 56%.
Subsequently, the interactions of different long-chain compounds on
the OGE and the effect on polymerization behavior are both discussed
Relative Contribution of Fasting and Postprandial Blood Glucose in Overall Glycemic Control: Post-Hoc Analysis of a Phase IV Randomized Trial
<p></p><p><b>Article full text</b></p>
<p><br></p>
<p>The full text of this article can
be found here<b>.</b> <a href="https://link.springer.com/article/10.1007/s13300-018-0403-7">https://link.springer.com/article/10.1007/s13300-018-0403-7</a></p><p></p><p></p><p>
</p><p><br></p>
<p><b>Provide enhanced content for this
article</b></p>
<p><br></p>
<p>If you are an author of this
publication and would like to provide additional enhanced content for your
article then please contact <a href="http://www.medengine.com/Redeem/Ć¢ĀĀmailto:[email protected]Ć¢ĀĀ"><b>[email protected]</b></a>.</p>
<p><br></p>
<p>The journal offers a range of
additional features designed to increase visibility and readership. All
features will be thoroughly peer reviewed to ensure the content is of the
highest scientific standard and all features are marked as āpeer reviewedā to
ensure readers are aware that the content has been reviewed to the same level
as the articles they are being presented alongside. Moreover, all sponsorship
and disclosure information is included to provide complete transparency and
adherence to good publication practices. This ensures that however the content
is reached the reader has a full understanding of its origin. No fees are
charged for hosting additional open access content.</p>
<p><br></p>
<p>Other enhanced features include,
but are not limited to:</p>
<p><br></p>
<p>ā¢ Slide decks</p>
<p>ā¢ Videos and animations</p>
<p>ā¢ Audio abstracts</p>
<p>ā¢ Audio slides</p><br><p></p
- ā¦